FDA designee Califf defends his pharma ties; Samsung's Enbrel biosim up for EU nod;

@FierceBiotech: GC-1 drug shifts bad 'white' fat into good, calorie-burning 'brown' fat in mice. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Don't want to hear about how many drug approvals a Big Pharma has received in the last 5 years. Small $$ drugs don't mean much at all. | Follow @JohnCFierce

@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce

> Robert Califf, President Barack Obama's nominee to lead the FDA, defended his ties to the pharma industry in a Senate confirmation hearing. Califf previously ran Duke University's in-house CRO and has worked on many studies funded by drugmakers. News

> European regulators are considering whether to approve an Enbrel biosimilar from Samsung Bioepis, potentially altering the market for rheumatoid arthritis injections on the continent. Item

Pharma News

@FiercePharma: WHO meeting could change strain selection for flu vaccines. More from FierceVaccines | Follow @FiercePharma

@EricPFierce: There are lots changes going on among generics producers, but here are the top players. Feature | Follow @EricPFierce

> Advera Health: Novartis, GSK asthma meds linked to more side effects than Merck drugs. Report

> U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha. Story

> Cancer, hep C and other specialty meds to drive global drug market to $1.4T by 2020. Article

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Scientific recall of its cardiology guidewire deemed Class 1 by FDA. Article | Follow @VarunSaxena2

@EmilyWFierce: : Discounts not enough to sway U.K. gatekeeper to back Roche's Kadcyla. FiercePharmaMarketing report | Follow @EmilyWFierce

> Medtronic buys Aircraft Medical for $110M in bid to cut respiratory failure from unsuccessful intubation. Report

> FDA flags underactive thryoid cases in babies receiving iodine-containing contrast agents. Article

> CMS to penalize underperforming hospitals when it comes to hip and knee replacement. Story

Biotech Research News

> Generic alcoholism drug used to flush dormant HIV. Report

> UCSD team targeting new stress pathway in Alzheimer's program. More

> CRISPR/Cas9 2.0: Research team offers an upgrade to gene editing tech. Story

> Bone microenvironment offers new approach on prostate cancer. Item

> GC-1 drug shifts bad 'white' fat into good, calorie-burning 'brown' fat in mice. Article

Vaccines News

> Scripps scientists ID weakness-attacking antibodies in pursuit of HIV vaccine. More

> FDA panel to examine 'maternal vaccines' to protect infants. Report

> Researchers tout vaccine's potential to lower cholesterol. Story

> GlaxoSmithKline Ebola vaccine shows safety in PhI. Article

> WHO meeting could change strain selection for flu vaccines. Item

Pharma Marketing News

> Just say no to drugs (advertising): AMA votes to ban DTC ads. More

> AbbVie's Humira repeats, joined by BMS' Opdivo in leading TV spending for October. Report

> Pay attention, pharma marketers: Men are checking out your brand marketing. Article

> Amgen's Repatha gets a thumbs-down from U.K. cost-effectiveness watchdogs. Item

> Discounts not enough to sway U.K. gatekeeper to back Roche's Kadcyla. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.